AVEO Oncology (Nasdaq: AVEO) 19.4% LOWER; announced that it has received written feedback from the U.S. Food and Drug Administration ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE